Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia
- Research Opportunity
- PhD, Masters by Research, Honours, Master of Biomedical Science
- Project Status
- Medicine and Radiology
- Royal Melbourne Hospital
|Professor Terence O'Brienemail@example.com||8344 5490||Personal web page|
|Professor Dennis Velakoulisfirstname.lastname@example.org||Personal web page|
Frontotemporal dementia (FTD) is generally due to abnormalities either in a protein called tau (45%) or a protein called TDP-43 (45%). In both types of FTD the protein aggregates into ‘clumps’ that block brain cell function. There are currently no treatments for either type of FTD.
Our group has successfully run several research trials using a drug called sodium selenate that prevents the aggregation of tau in brain cells. We have shown that sodium selenate is safe in humans and that it has measurable benefits in Alzheimers disease (a different type of dementia to FTD). This study is an early phase study in which participants with FTD receive sodium selenate and are followed over 12 months. During this period standardised measurements of safety, cognition and neuroimaging (MRI, PET) will be undertaken.
This research project is available to PhD, Masters by Research, Honours, Master of Biomedical Science students to join as part of their thesis.
Please contact the supervisor to discuss your options.